PAVmed
PAVM
94 hedge funds and large institutions have $27M invested in PAVmed in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 26 increasing their positions, 34 reducing their positions, and 24 closing their positions.
2% more call options, than puts
Call options by funds: $248K | Put options by funds: $244K
0.02% less ownership
Funds ownership: 0.07% → 0.05% (-0.02%)
10% less funds holding
Funds holding: 105 → 94 (-11)
24% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 34
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
59% less capital invested
Capital invested by funds: $65.5M → $27M (-$38.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCS
Levin Capital Strategies
New York
|
+$512K |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$245K |
| 3 |
State Street
Boston,
Massachusetts
|
+$200K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$193K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
+$174K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$2.22M |
| 2 |
Two Sigma Advisers
New York
|
-$1.48M |
| 3 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$1.4M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.33M |
| 5 |
Morgan Stanley
New York
|
-$1.1M |
PAVM Hedge Fund Activity: Q1 2022 in Review
94 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in PAVmed (PAVM) for Q1 2022, worth a combined $27M — down 59% from $65.5M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PAVM and 14 opened new positions — a net loss of 10 holders — while 34 trimmed existing stakes and 26 added.
The largest buyer was Levin Capital Strategies, adding an estimated $512K. The largest seller was Two Sigma Investments, cutting an estimated $2.22M.
- 94 institutional investors held PAVmed (PAVM) as of Q1 2022, down from 105 in Q4 2021.
- Funds reported $27M of PAVmed stock for Q1 2022, down 59% quarter-over-quarter.
- 14 funds opened new PAVmed positions in Q1 2022 and 24 closed out, a net change of -10 holders.
- The largest PAVmed buyer in Q1 2022 was Levin Capital Strategies, an estimated $512K added.
- The largest PAVmed seller in Q1 2022 was Two Sigma Investments, an estimated $2.22M sold.
Based on aggregated 13F filings for Q1 2022.